Trial Profile

A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behcet Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary)
Indications Behcet's syndrome; Genital ulcer; Oral ulcer; Panuveitis; Posterior uveitis; Retinal disorders; Vasculitis
Focus Proof of concept; Therapeutic Use
Acronyms STELABEC

Most Recent Events

02 Dec 2021 Primary endpoint has been met (Number of oral ulcers at week 24 compared to baseline)as per Results published in the Journal of the American Academy of Dermatology
02 Dec 2021 Results published in the Journal of the American Academy of Dermatology
12 Nov 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com